Description
GLP-1 (Liraglutide) Peptide Vials
| GLP-1 | |
| CAS Number | 87805-34-3 |
| Molar Mass | 3297.6g.mol-1 |
| Chemical Formula | C149H226N40O45 |
| IUPAC Name | (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid |
Introduction
GLP-1 (Liraglutide) Vials are a research-grade product developed for scientific investigations and experimentation. Strictly intended for research purposes, these vials contain Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, known for its potential therapeutic effects.
Key Characteristics
GLP-1 (Liraglutide) Vials boast exceptional characteristics essential for rigorous scientific investigations. The product is distinguished by its remarkable purity, featuring highly purified Liraglutide that ensures the accuracy and reliability of research outcomes. Formulated with a keen eye on stability, these vials are designed to maintain their integrity over the long term when stored under appropriate conditions. This stability is crucial for researchers seeking consistent and dependable results throughout the duration of their experiments. Furthermore, precision is a hallmark of this product, with each vial containing an exact and carefully measured dosage. This precision ensures that researchers can conduct experiments with confidence, knowing that the administered amounts are consistent, contributing to the reliability and reproducibility of their findings.
Research Applications
GLP-1 (Liraglutide) Vials find applications in a variety of research areas, with a focus on understanding the molecular mechanisms and potential therapeutic benefits associated with GLP-1 analogs.
Research Benefits
Liraglutide and Obesity
Numerous research studies have indicated that Liraglutide may play a role in managing obesity. Experimental models have shown a reduction in food intake and body weight, suggesting its potential as a subject of study for obesity-related research.
Liraglutide and Type-2 Diabetes
Research on Liraglutide’s impact on Type-2 Diabetes has demonstrated its ability to improve glycemic control. Studies suggest that Liraglutide may enhance insulin sensitivity and stimulate insulin secretion, making it a valuable component in diabetes-focused research.
Liraglutide and Bone Loss
Exploratory studies have proposed a potential link between GLP-1 analogs like Liraglutide and bone health. Some findings suggest a positive impact on bone density and the prevention of bone loss, making it an intriguing area of investigation for researchers in the field of skeletal health.
Summary
In conclusion, GLP-1 (Liraglutide) Vials are a specialized research tool designed to facilitate scientific inquiry into the multifaceted benefits of Liraglutide. From addressing obesity-related concerns to investigating its impact on Type-2 Diabetes and potential associations with bone health, researchers can leverage these vials to contribute to the growing body of knowledge in these critical areas. It is imperative to emphasize that this product is strictly for research purposes and not intended for human consumption.
Disclaimer
This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.
Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).
Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.
Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].
IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.
References:
- Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017 Mar;3(1):3-14. doi: 10.1002/osp4.84. Epub 2016 Dec 19. PMID: 28392927; PMCID: PMC5358074. [Read More]
- Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004 Aug;27(8):1915-21. doi: 10.2337/diacare.27.8.1915. PMID: 15277417. [Read More]
- Wen B, Zhao L, Zhao H, Wang X. Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis. Exp Ther Med. 2018 Jun;15(6):5077-5083. doi: 10.3892/etm.2018.6043. Epub 2018 Apr 10. PMID: 29805533; PMCID: PMC5958780.. [Read More]
William Flores –
It greatly helped maintain my overall health.